Aromics recieves 1 M€ from the European Union to boost its drug against the asbestos-related hallmark cancer Blog Post

Aromics, a biotech company located at the Barcelona Science Park (PCB), has been awarded with 1,085.659€ from the European Union – through the SME instrument of the Horizon 2020 (H2020-EIC-SMEInst-2018-2020-Phase 2)– for the development of the BERMES project, whose objective is the completion of the regulatory preclinics of NAX035, an innovative therapy for the treatment of malignant mesothelioma, an aggressive and highly refractory tumor directly related to asbestos exposure.

 

GAEM Foundation: prize-winner in the sixth ‘Solidarity Territories’ awards ceremony Blog Post

The GAEM Foundation was recognised in the sixth edition of BBVA’s and the Fundació Antigues Caixes Catalanes (FACC) ‘Solidarity Territories‘ awards ceremony, winning a €6,000 donation for its “QUEREMOS curarnos. Esclerosis Múltiple” [WE WANT to get cured. Multiple Sclerosis] initiative. This project aims to accelerate the transfer of therapeutic solutions through its Project Accelerator programme, speeding up treatment accessibility to multiple sclerosis patients and helping to improve patient quality of life and to cure the disease.

 

Embryotools achieves the world’s first pregnancy with a new nuclear transfer technique for treating infertility Blog Post

Researchers from the Spanish centre Embryotools —with headquarters in the Barcelona Science Park (Parc Científic de Barcelona, PCB) — are participating in a landmark scientific event in Greece that will shape the future of assisted reproduction. In a pilot clinical trial conducted on women, which is being sponsored by the assisted reproduction centre Institute of Life in Athens, Spanish scientists have achieved the world’s first pregnancy that uses the Maternal Spindle Transfer technique to solve problems of infertility.

 

Europe looks to cells for a healthier future Blog Post

Researchers from the Centro Nacional de Análisis Genómico (CNAG-CRG) –based in the Barcelona Science Park and integrated into the Centre for Genomic Regulation (CRG) take part in the LifeTime consortium, which aims at understanding the constant changes within cells and their relationship to disease. The initiative will receive one million euros to devise a plan how to embed its vision into the European research and innovation landscape.

 

Joan J. Guinovart awarded with the Royal Academy of Pharmacy of Catalonia Prize Blog Post

Joan J. Guinovart was awarded XXII Prize from the Royal Academy of Pharmacy of Catalonia in recognition of his significant contribution to the field of pharmacy in Catalonia, as well as in Spain and the rest of the world. Guinovart served as the first director of the Institute for Research in Biomedicine (IRB Barcelona) and is the group leader of the Metabolic Engineering and Diabetes Therapy lab at the same institute based in PCB.

 

Defective glial cells can push neurons toward Parkinson’s disease Blog Post

Defective versions of human brain cells called astrocytes are linked to the buildup of a toxic protein that is one the hallmarks of Parkinson’s disease. This is one of the main conclusions of a study led by Antonella Consiglio, researcher at the Institute of Biomedicine of the University of Barcelona (IBUB) in the Barcelona Science Park, and the Bellvitge Biomedical Research Institute (IDIBELL), and Àngel Raya, from the Center of Regenerative Medicine in Barcelona (CMR[B]-IDIBELL).

 

Researchers at IRB Barcelona develop a tool to tackle resistance in cancer Blog Post

The lab headed by Modesto Orozco at the Institute for Research in Biomedicine (IRB Barcelona) in the Barcelona Science Park has developed a tool to tackle resistance in cancer. The therapeutic approach has been validated in breast cancer cells in vitro, and the results have been published in the scientific journal Chemical Communications.

 

Proteins can transfer electrons at a distance Blog Post

Researchers from the Institute for Bioengineering of Catalonia (IBEC) al PCB have published a study in Nature Communications that reveals that electron transfer can take place while a protein is approaching its partner site, and not only when the proteins are engaged, as was previously thought. The results open up a new way of thinking about how proteins interact, and can have implications in a better understanding of many processes – such as photosynthesis, respiration and detoxification – in which electron transfer plays an important role.

 

Iproteos, IBEC and VHIR to develop an innovative therapy against solid tumors Blog Post

The biotechnology company Iproteos and the Institute of Bioengineering of Catalonia (IBEC), based at the Barcelona Science Park (PCB), and the Vall d’Hebron Research Institute (VHIR) are set to develop an innovative treatment to slow down, stop and even reverse the growth of solid tumors, which represent more than 90% of cancer cases. The project, which received €935,000 from the Ministry of Science, Innovation and Universities, through of the call Retos Colaboración, will focus in its first phase on two of the most common solid tumors in children and adolescents, rhabdomyosarcoma and neuroblastoma, as well as in lung and colon cancer, which have the highest mortality rate in adults.